Open AccessApplication Effect Evaluation of Telmisartan combined with Spironolactone after Catheter Ablation of Patients with Paroxysmal Atrial Fibrillation
Author(s) -
Rongcheng Zhao,
Juan Han,
Lei Zhao
Publication year - 2021
Publication title -
journal of clinical and nursing research
Language(s) - English
Resource type - Journals
eISSN - 2208-3693
pISSN - 2208-3685
DOI - 10.26689/jcnr.v5i3.2156
Subject(s) - telmisartan , medicine , spironolactone , atrial fibrillation , paroxysmal atrial fibrillation , catheter ablation , cardiology , catheter , ablation , radiofrequency ablation , anesthesia , surgery , heart failure , blood pressure
Objective: To evaluate the application effect of telmisartan combined with spironolactone after catheter ablation of patients with paroxysmal atrial fibrillation. Methods: 80 cases of patients with paroxysmal atrial fibrillation who received radiofrequency catheter ablation treatment from March 2013 to March 2016 in our hospital were randomly selected, these patients were divided into two groups according to the treatment methods, namely, the telmisartan with Spironolactone treatment group (combined treatment group, n=40) and the conventional therapy group (n=40). The hs-CRP, NT-proBNP, LAD and recurrence of the two groups were analyzed. Results: The hs-CRP, NT-proBNP levels after 3 months of the combined treatment group were significantly lower (P<0.05), the recurrence rate 10.0% (4/40) was significantly lower than the conventional therapy group 27.5% (11/40) (P<0.05), the time to recurrence was significantly longer than the conventional therapy group (P<0.05). Conclusion: The application effects of telmisartan combined with spironolactone after catheter ablation in the treatment of patients with paroxysmal atrial fibrillation are better than conventional therapy.